Genmab A/S (GEN.CO) Release: Prospectus Regarding Admittance to Trading and Official Listing on NASDAQ OMX Copenhagen A/S of Shares Issued in Connection With the Daratumumab Agreement Has Been Approved
10/16/2012 9:45:30 AM
openhagen, Denmark; October 16, 2012 – Genmab A/S (OMX: GEN) announced today that the Danish Financial Supervisory Authority has approved the prospectus prepared in connection with the admittance to trading and official listing on NASDAQ OMX Copenhagen A/S of shares issued to Johnson & Johnson Development Corporation in a private placement. The issue of 5,400,000 shares is in connection with the daratumumab license agreement with Janssen Biotech, Inc. signed August 30, 2012 (Company Announcements 20, 21 and 22). The prospectus is in English and includes a Danish summary. The prospectus is available on the Genmab website www.genmab.com.